Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
Clinical Epigenetics volume 14, Article number: 97 (2022)
Correction: Clinical Epigenetics (2018) 10:64 https://doi.org/10.1186/s13148-018-0495-y
Li W, et al. miR-29c plays a suppressive role in breastcancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenet. 2018;10:64. https://doi.org/10.1186/s13148-018-0495-y.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Sequence of DNMT3B siRNA. Table S2. Primers of miR-29c and DNMT3B. Table S3. Primers of TIMP3 for methylation specific PCR and unmethylation PCR. Figure S1. Quantification of protein expression level of DNMT3B in human breastcancer tissues and the paired adjacent non-tumor tissues. Figure S2. Migration and invasion of cells. Figure S3. miR-29c inhibited proliferation, migration and invasion, colony formation and growth in 3D Matrigel of MDA-MB-436 cells. Figure S4. DNMT3B promoted migration, invasion, colony formation and growth in 3D Matrigel of MDA-MB-231 miR-29c cells. Figure S5. Colony formation of cells. Figure S6. miR-29c reduced luciferase activity of wild type 3’UTR of DNMT3B-luciferase reporter, and not the mutant type 3’UTR of DNMT3B reporter in MCF-7 cells. Figure S7. Expression of DNMT3B, TIMP3, STAT1 and FOXO1. Figure S8. Migration and invasion of cells.
About this article
Cite this article
Li, W., Yi, J., Zheng, X. et al. Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenet 14, 97 (2022). https://doi.org/10.1186/s13148-022-01317-4